Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Spero Therapeutics (NASDAQ:SPRO) reported its Q3 earnings results on Monday, November 13, 2023 at 04:05 PM.
Here's what investors need to know about the announcement.
Spero Therapeutics missed estimated earnings by 100.0%, reporting an EPS of $-0.06 versus an estimate of $-0.03.
Revenue was up $23.47 million from the same period last year.
Last quarter the company beat on EPS by $0.11 which was followed by a 3.45% drop in the share price the next day.
Here's a look at Spero Therapeutics's past performance:
Quarter | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
---|---|---|---|---|
EPS Estimate | -0.34 | -0.33 | 0.04 | -0.30 |
EPS Actual | -0.23 | -0.25 | 0.55 | -0.33 |
Revenue Estimate | 1.07M | 1.00M | 22.87M | 5.42M |
Revenue Actual | 2.72M | 2.07M | 47.44M | 2.01M |
To track all earnings releases for Spero Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: SPRO